^
    Back
    Association details:
    Biomarker:MET D1228N
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

    Excerpt:
    An acquired mutation in the MET kinase domain, D1228N, was found at time of progression on crizotinib in a patient with MET exon 14 skipping.
    DOI:
    10.1016/j.jtho.2016.06.013